NCT06963697

Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

• Status: Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Jaime Leandro Foundation for Therapeutic Cancer Vaccines · Academic / Other
• Sex: All
• Age: 12 Years
• Healthy volunteers: —

Summary

This is an intermediate patient expanded access protocol for treatment of patients with local or metastatic solid tumors with a neoantigen synthetic long peptide vaccine.

Conditions

• Cancer

Interventions

Type	Name	Description
BIOLOGICAL	Personalized Synthetic Long Peptide Vaccine	Neoantigen synthetic long peptide vaccines are composed of synthetic long peptides which are 8-35 amino acids in length and designed to induce immune responses to cancer neoantigens identified by exome sequencing. Neoantigen synthetic long peptide vaccines will be co-administered with poly-ICLC, an innate immune adjuvant capable of activating TLR3 and other pathways.

Timeline

• First posted: 2025-05-09
• Last updated: 2026-01-15

Locations

1 site across 1 country: United States